IP Library › Granted Patent US 11,104,875
Granted Patent B2
US 11,104,875 · App. 16/071,941 · Granted Aug 31, 2021

Linked perfusion to continuous-flow stirred-tank reactor cell culture system

Inventors: Gregory Walter Hiller (Wakefield, MA); Matthew Paul Gagnon (Medford, MA); Jonathan Coffman (Union City, CA)
Assignee: Boehringer Ingelheim International GmbH
C12M23/58C07K16/00C12M23/40C12M27/02C12M29/10C12N5/0018C12N5/0682C12P21/02C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,875
App. No.
16/071,941
Granted
Aug 31, 2021
Kind
B2
Abstract

Methods of protein production in a linked culture and production bioreactor system are provided. Such methods include a culture bioreactor (N-1 bioreactor) linked to production bioreactor (N bioreactor). More specifically, the methods include (a) culturing cells with a gene that encodes the protein of interest in a continuous perfusion culture bioreactor (N-1 bioreactor); inoculating a continuously stirred tank reactor (CSTR) production bioreactor (N bioreactor) with cells obtained from step (a); and culturing the cells in the CSTR production bioreactor under conditions that allow production of the protein of interest.

Claims (24)

1. A method of producing a protein of interest, comprising:

(a) culturing cells comprising a gene that encodes the protein of interest in a culture bioreactor (N-1 bioreactor);

(b) inoculating a production bioreactor (N bioreactor) with cells obtained from step (a); and

(c) culturing the cells in the production bioreactor under conditions that allow production of the protein of interest,

wherein the inoculation in step (b) is by transferring cells from the culture bioreactor to the production bioreactor,

wherein the cell transfer is by cell bleed in semi-continuous mode comprising the cell transfer once at every period of time from 2 minutes to 24 hours or any interval there between.

2. The method according to claim 1 , wherein the method further comprises step (d) harvesting the protein of interest from the production bioreactor.

3. The method according to claim 1 , wherein the culture bioreactor is a continuous perfusion culture bioreactor and the production bioreactor is a continuously stirred tank reactor (CSTR) production bioreactor.

4. The method according to claim 1 , wherein the production bioreactor has no cell retention device.

5. The method according to claim 1 , wherein volume ratio of the culture bioreactor to the production bioreactor is about 1:1 to about 1:20.

6. The method according to claim 1 , wherein step (a) alternates between a first and second culture bioreactors to allow for renewal and continuous production of culture cells for use in step (b).

7. The method according to claim 6 , wherein the second culture bioreactor is a continuous perfusion culture bioreactor.

8. The method according to claim 1 , wherein the production bioreactor operates continuously for a period of greater than 3 weeks.

9. The method according to claim 2 , wherein harvesting step (d) is continuous.

10. The method according to claim 1 , wherein the cells are C.H.O. cells, HEK-293 cells, VERO cells, N.S.O. cells, PER.C6 cells, Sp2/0 cells, B.H.K. cells, MDCK cells, MDBK cells or C.O.S. cells.

11. The method according to claim 1 , wherein the production bioreactor has a volumetric productivity of at least 0.6 grams per liter per day for a period of at least 14 days.

12. The method according to claim 1 , wherein the production bioreactor has a product residence time of about 1 to about 10 days.

13. The method according to claim 1 , wherein the production bioreactor has a dilution rate of about 1 to about 0.1 volume per day.

14. The method according to claim 1 , wherein volume ratio of the culture bioreactor to the production bioreactor is about 1:5.

15. The method according to claim 1 , wherein the production bioreactor operates continuously for a period of greater than 4 weeks.

16. The method according to claim 1 , wherein the production bioreactor operates continuously for a period of greater than 5 weeks.

17. The method according to claim 1 , wherein the production bioreactor operates continuously for a period of greater than 6 weeks.

18. The method according to claim 1 , wherein the production bioreactor has a volumetric productivity of at least 0.6 grams per liter per day for a period of at least 20 days.

19. The method according to claim 1 , wherein the production bioreactor has a volumetric productivity of at least 0.6 grams per liter per day for a period of at least 30 days.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: COFFMAN, JONATHAN
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 048199/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 048201/0128 →
Continuity (3)
Provisional Application 62331619 · May 4, 2016
Provisional Application 62287194 · Jan 26, 2016
Related Publication 20190031997A1 · Jan 31, 2019
Cited By (5)
US 12,352,625 US 12,460,170 US 12,509,655 US 12,668,774 US 12,686,847